3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Neoplasms
12
Breast Neoplasms
7
Neoplasm Metastasis
5
Lymphoma
5
Multiple Myeloma
4
Leukemia
4
Hematologic Neoplasms
4
Colorectal Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Depression
3
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Ovarian Neoplasms
2
Motor Activity
2
Malignant Female Reproductive System Neoplasm
2
Glioblastoma
2
Fatigue
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Caregiver Burden
2
Anxiety Disorders
2
Advanced Malignant Solid Neoplasm
2
Thyroid Neoplasms
1
Stroke
1
Stress Disorders, Post-Traumatic
1
Squamous Cell Carcinoma of Head and Neck
1
Sleep Initiation and Maintenance Disorders
1
Signs and Symptoms
1
Interventions
Paclitaxel
15
Carboplatin
9
liposomal doxorubicin
8
Bevacizumab
8
pembrolizumab
7
Topotecan
6
olaparib
4
mirvetuximab soravtansine
4
Nivolumab
4
Cyclophosphamide
4
niraparib
3
fludarabine
3
Gemcitabine
3
Drug Therapy
3
rucaparib
2
ribociclib
2
pegfilgrastim
2
palbociclib
2
oregovomab
2
fludarabine phosphate
2
Irinotecan
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fulvestrant
2
Cisplatin
2
Blood Specimen Collection
2
1-dodecylpyridoxal
2
trastuzumab deruxtecan
1
sacituzumab govitecan
1
isoquercitrin
1
irinotecan sucrosofate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
Palliative Care
×
1 year
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled